Supplementary information
: MK and PLP counts before and after a 2-hour perfusion. Data are presented as mean ± SEM, with n = 8 for experiments with 5 chips, and n = 12 for experiments without chip. Data in the figure 4a and 4b panels correspond to experiments presented in this table with 5 chips (microfluidic device) or without chip (control). η is the platelet yield defined by equation (1). 0 and f stand for initial and final conditions.
Supplementary videos
Video 1. This video illustrates the capture and the elongation of a MK in a bioreactor. The first part of the video is a movie recorded with a high-speed camera. It illustrates the capture of a MK onto a pillar. The MK is advected by the flow before encountering a VWF coated pillar. Once captured by the pillar, the MK rolls around the pillar by translocation. The second part of the video is a time-lapse recording of a MK elongation. The second pillar starting from the left of the frame captures a MK. The MK is attached downstream of the pillar after translocating around it as explained in the first part of the video. The MK undergoes fluid shear and starts elongating. After 15 min, the elongation starts modifying its shape to form beads on a string (right side of the frame). In both parts of the video, the white arrow represents the mean flow direction. The scale bars represent 20 µm.
Video 2. This video is a time-lapse recording, illustrating platelet and proplatelet releases from an elongated MK. The MK is attached downstream of the left pillar by the mechanism explained in Video 1, and has already started elongating at the beginning of the video. Five ruptures of the beads-on-a-string shape elongation occur and are shown with the triangular arrows. Platelets and proplatelets are released in the flow at high speed explaining their disappearance when a rupture occurs. The white arrow represents the mean flow direction. The scale bar represents 20 µm. On the other hand, produced platelets were collected at the outlet of the microfluidic device after a perfusion of 2 hours with 100 000 MK/ml(i) and 400 000 MK/ml (ii) and their function was controlled by indirect immunofluorescence labeling with a PAC-1 antibody, revealed by a secondary AlexaFluor488 anti-mouse antibody and AlexaFluor546 phalloidin for F-actin staining, and performed in the absence (left panels) or presence (right panels) of TRAP. Scale bar: 5 µm. This results show that the platelets produced from the diluted and concentrated conditions present the same profile; they are not activated but stay functional. In conclusion, even if MKs cluster into clogs, they are not activated in them and produce platelets that are not activated and stay functional. Figure S7 : Comparison of fresh washed platelets isolated from blood with cells collected at the exit of the microfluidic device. The FSC/SSC dot plot of the isolated platelets from blood allows to draw a platelet gate, which is applied to calculate the % of PLP in the cells collected at the exit of the microfluidic device. Fluorescence intensity of CD61, the β3 subunit of the αIIbβ3 receptor, is shown and was obtained using the GPscreen receptor density assay (Biocytex) depicted in Figure 5b . This quantitative assay allows to determine the expression of CD61 at the surface of platelets produced in the microfluidic device (64 633 ± 8 789 receptor/platelet; 3 experiments). This value compares with the density provided by the manufacturer for a large panel of normal blood platelets (53 000 ± 12 000). Expression of CD62P at the surface of platelets produced in the microfluidic device is 35.7% vs 17.8% for blood platelets. PAC1 antigen binding depicts the conformational change of αIIbβ3 receptor following platelet activation with 10 µM TRAP. Bold line depicts the platelet response to activation, whereas the thin line shows the amount of PAC1-FITC fluorescence in the absence of activation. Values are 58.7% and 37.6% positive platelets respectively for blood platelets and for platelets produced in the microfluidic device.
